Angiogenesis: Noninvasive quantitative assessment with contrast-enhanced functional us in murine model

Radiology

Volumn 239, Issue 3, 2006, Pages 730-739

  Lucidarme, Olivier ^a,e   Kono, Yuko ^a   Corbeil, Jacqueline ^a   Choi, Sang Hee ^a,f   Golmard, Jean Louis ^c   Varner, Judith ^b   Mattrey, Robert F ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c SORBONNE UNIVERSITÉ   (France)

^d MRI Institute   (United States)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CD31 ANTIBODY; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VOLUME; CALCULATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DOSE TIME EFFECT RELATION; ECHOGRAPHY; HISTOPATHOLOGY; IMPLANT; MATHEMATICAL MODEL; MICROBUBBLE; MICROVASCULAR DENSITY; MICROVASCULARIZATION; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; QUANTITATIVE FUNCTIONAL ULTRASONOGRAPHY;

ANIMALS; ANTIGENS, CD31; BLOOD VOLUME; CONTRAST MEDIA; FIBROBLAST GROWTH FACTOR 2; FLUOROCARBONS; GELS; HUMANS; IMAGE ENHANCEMENT; MICE; MICROBUBBLES; MICROCIRCULATION; MODELS, ANIMAL; NEOVASCULARIZATION, PHYSIOLOGIC; PROSTHESES AND IMPLANTS; RANDOM ALLOCATION; SKIN; TIME FACTORS; ULTRASONOGRAPHY;

EID: 33744821896     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2392040986     Document Type: Article

References (45)

1. Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001;7:1888-1893.
2. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002;29:27-36.
3. Kohn EC, Reed E, Sarosy GA, et al. A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction. Clin Cancer Res 2001;7:1600-1609.
4. Kudelka AP, Verschraegen CF, Lover E. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N Engl J Med 1998;338:991-992.
5. Offodile R, Walton T, Lee M, Stiles A, Nguyen M. Regression of metastatic breast cancer in a patient treated with the antiangiogenic drug TNP-470. Tumori 1999;85:51-53.
6. Vine AK, Brewer GJ. Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Trans Am Ophthalmol Soc 2002;100:73-76.
7. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214.
8. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:203-216.
9. Schor AM, Pendleton N, Pazouki S, et al. Assessment of vascularity in histological sections: effects of methodology and value as an index of angiogenesis in breast tumours. Histochem J 1998;30:849-856.
10. Pollard HE, Sadlowski AR, Bloch SH, et al. Contrast-assisted destruction-replenishment ultrasound for the assessment of tumor microvasculature in a rat model. Technol Cancer Res Treat 2002;1:459-470.
11. Schlosser T, Pohl C, Veltmann C, et al. Feasibility of the flash-replenishment concept in renal tissue: which parameters affect the assessment of the contrast replenishment? Ultrasound Med Biol 2001;27:937-944.
12. Seidel G, Claassen L, Meyer K, Vidal-Langwasser M. Evaluation of blood flow in the cerebral microcirculation: analysis of the refill kinetics during ultrasound contrast agent infusion. Ultrasound Med Biol 2001;27:1059-1064.
13. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 1998;97:473-483.
14. Wei K, Le E, Bin JP, Coggins M, Thorpe J, Kaul S. Quantification of renal blood flow with contrast-enhanced ultrasound. J Am Coll Cardiol 2001;37:1135-1140.
15. Forsberg F, Dicker AP, Thakur ML, et al. Comparing contrast-enhanced ultrasound to immunohistochemical markers of angiogenesis in a human melanoma xenograft model: preliminary results. Ultrasound Med Biol 2002;28:445-451.
16. Schroeder RJ, Hauff P, Bartels T, et al. Tumor vascularization in experimental melanomas: correlation between unenhanced and contrast enhanced power Doppler imaging and histological grading. Ultrasound Med Biol 2001;27:761-771.
17. Wilkening W, Postert T, Federlein J, Kono Y, Mattrey R, Ermert H. Ultrasonic assessment of perfusion conditions in the brain and in the liver. In: Schneider SC, Levy M, McAvoy BR, eds. Ultrasonics Symposium Proceedings. Vol 2. New York, NY: Institute of Electrical and Electronic Engineers, 2000; 1544-1348.
18. Lucidarme O, Kono Y, Corbeil J, Choi S, Mattrey R. Validation of ultrasound contrast destruction imaging for flow quantification. Ultrasound Med Biol 2003;29:1697-1704.
19. Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988;48:2641-2638.
20. Baatout S, Cheta N. Matrigel: a useful tool to study endothelial differentiation. Rom J Intern Med 1996;34:263-269.
21. Kleinman HK, McGarvey ML, Hassell JR, et al. Basement membrane complexes with bialogical activity. Biochemistry 1986;25:312-318.
22. Passaniti A, Taylor RM, Pili R, et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992;67:519-528.
23. Lucidarme O, Nguyen T, Kono Y, et al. Angiogenesis model for ultrasound contrast research: exploratory study. Acad Radiol 2004;11:4-12.
24. Frinking PJ, Céspedes E, Kirkhorn J, Torp H, de Jong N. A new ultrasound Contrast imaging approach based on the combination of multiple imaging pulses and a separate release burst. IEEE Trans Ultrason Ferroelectr Freq Control 2001;48:643-651.
25. Walker KW, Pantely GA, Sahn DJ. Ultrasound-mediated destruction of contrast agents: effect of ultrasound intensity, exposure, and frequency. Invest Radiol 1997;32:728-734.
26. Perflexane (AF0150, AFO 150, Imagent, Imavist). Drugs R D 2002;3:306-309.
27. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996;32A:2474-2484.
28. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-1887.
29. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
30. Bartko J. On various intraclass correlation reliability coefficients. Psychol Bull 1976;83:762-765.
31. Shrout P, Fleiss J. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979;86:420-428.
32. Fleiss J. The design and analysis of clinical experiments. New York, NY: Wiley, 1986.
33. Libutti SK, Choyke P, Carrasquillo JA, Bacharach S, Neumann RD. Monitoring responses to antiangiogenic agents using non-invasive imaging tests. Cancer J Sci Am 1999;5:252-256.
34. Jain RK, Schlenger K, Hockel M, Yuan F. Quantitative angiogenesis assays: progress and problems. Nat Med 1997;3:1203-1208.
35. Graham CH, Rivers J, Kerbel RS, Stankiewicz KS, White WL. Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas. Am J Pathol 1994;145:510-514.
36. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 1995;147:33-41.
37. Maeda K, Chung YS, Takatsuka S, et al. Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer 1995;72:319-323.
38. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1993;55:3964-3968.
39. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-409.
40. Iordanescu I, Becker C, Zetter B, Dunning P, Taylor GA. Tumor vascularity: evaluation in a murine model with contrast-enhanced color Doppler US effect of angiogenesis inhibitors. Radiology 2002;222:460-467.
41. Kim SW, Park SS, Ahn SJ, et al. Identification of angiogenesis in primary breast carcinoma according to the image analysis. Breast Cancer Res Treat 2002;74:121-129.
42. Huber S, Vesely M, Zuna I, Delorme S, Czembirek H. Fibroadenomas: computer-assisted quantitative evaluation of contrast-enhanced power Doppler features and correlation with histopathology. Ultrasound Med Biol 2001;27:3-11.
43. Strohmeyer D, Frauscher F, Klauser A, et al. Contrast-enhanced transrectal color doppler ultrasonography (TRCDCUS) for assessment of angiogenesis in prostate cancer. Anticancer Res 2001;21:2907-2913.
44. Plunkett ML, Hailey JA. An in vivo quantitative angiogenesis model using tumor cells entrapped in alginate. Lab Invest 1990;62:510-517.
45. Eyding J, Wilkening VV, Reckhardt M, et al. Contrast burst depletion imaging (CODIM): a new imaging procedure and analysis method for semiquantitative ultrasonic perfusion imaging. Stroke 2003;34:77-83.